# Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

> **NCT03704246** · PHASE2 · UNKNOWN · sponsor: **Taizhou Hanzhong biomedical co. LTD** · enrollment: 123 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT03704246
- **Lead sponsor:** Taizhou Hanzhong biomedical co. LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-30
- **Primary completion:** 2019-12-30
- **Final completion:** 2021-03-30
- **Target enrollment:** 123 (ESTIMATED)
- **Last updated:** 2021-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03704246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03704246, "Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03704246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*